Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2020 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean calik m[au] (141 results)?
In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies.
Pichinuk E, Chalik M, Benhar I, Ginat-Koton R, Ziv R, Smorodinsky NI, Haran G, Garbar C, Bensussan A, Meeker A, Guillaume T, Rubinstein DB, Wreschner DH. Pichinuk E, et al. Among authors: chalik m. Cancer Immunol Immunother. 2020 Jul;69(7):1337-1352. doi: 10.1007/s00262-020-02547-2. Epub 2020 Mar 26. Cancer Immunol Immunother. 2020. PMID: 32219500
Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells.
Pichinuk E, Benhar I, Jacobi O, Chalik M, Weiss L, Ziv R, Sympson C, Karwa A, Smorodinsky NI, Rubinstein DB, Wreschner DH. Pichinuk E, et al. Among authors: chalik m. Cancer Res. 2012 Jul 1;72(13):3324-36. doi: 10.1158/0008-5472.CAN-12-0067. Epub 2012 Apr 16. Cancer Res. 2012. PMID: 22507854
LY6S, a New IFN-Inducible Human Member of the Ly6a Subfamily Expressed by Spleen Cells and Associated with Inflammation and Viral Resistance.
Shmerling M, Chalik M, Smorodinsky NI, Meeker A, Roy S, Sagi-Assif O, Meshel T, Danilevsky A, Shomron N, Levinger S, Nishry B, Baruchi D, Shargorodsky A, Ziv R, Sarusi-Portuguez A, Lahav M, Ehrlich M, Braschi B, Bruford E, Witz IP, Wreschner DH. Shmerling M, et al. Among authors: chalik m. Immunohorizons. 2022 Apr 19;6(4):253-272. doi: 10.4049/immunohorizons.2200018. Immunohorizons. 2022. PMID: 35440514